[{"orgOrder":0,"company":"Fina Biosolutions","sponsor":"VALANX Biotech","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRIA","productType":"Vaccine","year":"2024","type":"Licensing Agreement","leadProduct":"Conjugate Vaccine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Fina Biosolutions","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Fina Biosolutions \/ Fina Biosolutions","highestDevelopmentStatusID":"4","companyTruncated":"Fina Biosolutions \/ Fina Biosolutions"}]

Find Clinical Drug Pipeline Developments & Deals by Fina Biosolutions

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          BIO Partnering at JPM
                          Not Confirmed
                          BIO Partnering at JPM
                          Not Confirmed

                          Details : The licensing agreement will commercialize ready-to-conjugate vaccine carrier protein CRM197 enabling rapid development of conjugate vaccines such as the pneumococcal and meningococcal vaccines.

                          Brand Name : Undisclosed

                          Molecule Type : Vaccine

                          Upfront Cash : Undisclosed

                          October 29, 2024

                          Lead Product(s) : Conjugate Vaccine

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Preclinical

                          Recipient : VALANX Biotech

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank